Atossa Therapeutics (ATOS) Cash & Equivalents (2011 - 2026)

Atossa Therapeutics (ATOS) has reported Cash & Equivalents for 16 consecutive years, with $31.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 51.32% year-over-year to $31.7 million; the TTM figure through Mar 2026 stood at $31.7 million (down 51.32% YoY), while the FY2025 annual figure was $110000.0, down 99.85% from the prior year.
• Cash & Equivalents grew to $31.7 million in Q1 2026 per ATOS's latest filing, from $110000.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $131.5 million in Q1 2022 and bottomed at $110000.0 in Q4 2025.
• Historically, Cash & Equivalents has averaged $81.6 million across 5 years, with a median of $84.0 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 100709.09% — and 2025, when it plunged 99.85%.
• Atossa Therapeutics' Cash & Equivalents stood at $110.9 million in 2022, then decreased by 20.23% to $88.5 million in 2023, then retreated by 19.64% to $71.1 million in 2024, then slumped by 99.85% to $110000.0 in 2025, then surged by 28718.18% to $31.7 million in 2026.
• Business Quant data shows ATOS's Cash & Equivalents at $31.7 million in Q1 2026, $110000.0 in Q4 2025, and $51.8 million in Q3 2025.